Neurocrine Biosciences stockholders approve 2025 equity plan, elect four directors
At its May 21, 2025 annual meeting, Neurocrine Biosciences stockholders approved the 2025 Equity Incentive Plan and an amended and restated 2018 Employee Stock Purchase Plan, elected four Class II directors, and approved the advisory vote on executive compensation. Stockholders also ratified Ernst & Young LLP as the independent auditor for fiscal 2025. The filing reports the vote results, which are routine annual-meeting outcomes.
Key points
- The 2025 Equity Incentive Plan was approved with 72,648,862 votes for and 12,884,104 against.
- Four Class II directors were elected to three-year terms expiring at the 2028 annual meeting, including Richard F. Pops with 72,919,088 votes for.
- Of 98,938,234 shares entitled to vote, 90,434,193 were present in person or by proxy.
- Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 22, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.